ADVERTISEMENT
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

disease & medicine, clinical trials, drug development

Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Lisa Winter | Mar 16, 2021 | 2 min read
Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.
images related to COVID research
What’s Ahead for SARS-CoV-2 Research in 2021
Shawna Williams | Jan 8, 2021 | 5 min read
From new treatments to an investigation into the virus’s origins, here are some of the developments we can expect this year.
Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey and Christina Brennan | Dec 1, 2020 | 4 min read
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020 | 9 min read
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020 | 2 min read
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
New Drug Combo for ALS Slows Decline in Small Clinical Study
Jef Akst | Sep 3, 2020 | 3 min read
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
Gilead Urged to Explore Remdesivir Relative as COVID-19 Drug
Catherine Offord | Aug 11, 2020 | 2 min read
Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.
Remdesivir Shows Promise in Largest of Several Clinical Trials
Catherine Offord | Apr 30, 2020 | 3 min read
Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.
Clinical Trial of COVID-19 Vaccine Begins in Seattle
Amy Schleunes | Mar 16, 2020 | 2 min read
The first volunteer will receive a shot of the synthetic RNA vaccine today.
an illustration showing amyloid plaques around brain cells
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019 | 2 min read
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Interactive: Biomarkers in Blood Provide a Window into the Brain
Shawna Williams | Dec 1, 2019 | 1 min read
A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.
The Hunt for a Blood Test for Alzheimer’s Disease
Shawna Williams | Dec 1, 2019 | 10 min read
Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.
Early Results Are Positive for Experimental CRISPR Therapies
Jef Akst | Nov 19, 2019 | 2 min read
Two clinical trial participants—one with β-thalassemia and one with sickle cell disease—appeared to benefit from the gene-editing treatments with minimal side effects, according to the companies.
Trial of Gene Therapy for Duchenne Muscular Dystrophy Put on Hold
Catherine Offord | Nov 12, 2019 | 2 min read
The US Food and Drug Administration halts a study by Solid Biosciences after a patient experiences severe side effects following treatment.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019 | 2 min read
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment
Emily Makowski | Sep 16, 2019 | 1 min read
The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.
Recent Trials for Fragile X Syndrome Offer Hope
Randi Hagerman | Sep 1, 2019 | 10+ min read
Despite a solid understanding of the biological basis of fragile X syndrome, researchers have struggled to develop effective treatments.
Researchers Launch First Study of In Vivo CRISPR Therapy in Humans
Catherine Offord | Jul 26, 2019 | 1 min read
A trial is recruiting patients to test the gene-editing technology’s ability to treat an inherited form of blindness caused by a mutation in the CEP290 gene.
Donor-Derived iPS Cells Show Promise for Treating Eye Disease
Jef Akst | Apr 30, 2019 | 2 min read
Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.
ADVERTISEMENT